Category: 3. Business

  • Powell, Bessent met with U.S. Bank CEOs over Anthropic’s Mythos threat

    Powell, Bessent met with U.S. Bank CEOs over Anthropic’s Mythos threat

    Scott Bessent, Treasury Secretary (L), and Jerome Powell, chairman of the US Federal Reserve.

    Getty Images

    Federal Reserve Chairman Jerome Powell and Treasury Secretary Scott Bessent met with major U.S. bank CEOs this week to discuss the possible cyber risks raised by Anthropic’s Mythos model, CNBC confirmed Friday.

    The bank heads were already in Washington, D.C., for a Financial Services Forum board meeting, but a special gathering was called to discuss Mythos, according to people familiar with the matter, who asked not to be named in order to share information about a confidential matter.

    Bloomberg and the Financial Times were first to report the special meeting.

    Earlier this week, Anthropic rolled out the new artificial intelligence model, Claude Mythos Preview, in a limited capacity due to concerns that hackers could exploit its capabilities.

    Banking giant JPMorgan Chase was among the initial launch partners for the cybersecurity initiative, known as Project Glasswing. Other partners include Apple, Google, Microsoft and Nvidia.

    An official Anthropic told CNBC that it’s been in “ongoing discussions” with the U.S. government, including the Cybersecurity and Infrastructure Security Agency and the Center for AI Standards and Innovation, about Claude Mythos Preview’s cyber capabilities.

    Anthropic did not immediately respond to CNBC’s request for comment.

    This story is developing. Please refresh for updates.

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Continue Reading

  • Alexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseases

    CONTRAINDICATIONS

    • SOLIRIS is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection.

    WARNINGS AND PRECAUTIONS

    Serious Meningococcal Infections

    SOLIRIS, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

    Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with SOLIRIS. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information.

    If urgent SOLIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including SOLIRIS.   The benefits and risks of treatment with SOLIRIS, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by Neisseria meningitidis.

    Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

    Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of SOLIRIS in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated.

    ULTOMIRIS and SOLIRIS REMS

    Due to the risk of serious meningococcal infections, SOLIRIS is available only through a restricted program called ULTOMIRIS and SOLIRIS REMS.

    Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of SOLIRIS. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of SOLIRIS. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, the signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card with them at all times during and for 3 months following SOLIRIS treatment.

    Further information is available at www.UltSolREMS.com or 1-888-765-4747.

    Other Infections

    Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported.

    SOLIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections with Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with SOLIRIS may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP recommendations. Patients receiving SOLIRIS are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

    Thrombosis Prevention and Management

    The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

    Infusion-Related Reactions

    Administration of SOLIRIS may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion-related reaction which required discontinuation of SOLIRIS. Interrupt SOLIRIS infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

    ADVERSE REACTIONS

    Adverse Reactions for gMG

    The most frequently reported adverse reaction in the adult gMG placebo-controlled clinical trial (≥10%) was: musculoskeletal pain.

    Adverse Reactions for NMOSD

    The most frequently reported adverse reactions in the NMOSD placebo-controlled trial (≥10%) were: upper respiratory infection, nasopharyngitis, diarrhea, back pain, dizziness, influenza, arthralgia, pharyngitis, and contusion.

    DRUG INTERACTIONS

    Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion, or IVIg

    Concomitant use of SOLIRIS with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab concentrations and requires a supplemental dose of SOLIRIS.

    Neonatal Fc Receptor Blockers

    Concomitant use of SOLIRIS with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of SOLIRIS. Closely monitor for reduced effectiveness of SOLIRIS.

    To report SUSPECTED ADVERSE REACTIONS contact Alexion Pharmaceuticals, Inc. at 1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please see accompanying full Prescribing Information for SOLIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.

    Notes

    KOSELUGO® (selumetinib)

    KOSELUGO® (selumetinib) is a kinase inhibitor that blocks specific enzymes (MEK1 and MEK2), which are involved in stimulating cells to grow. In NF1, these enzymes are overactive, causing tumor cells to grow in an unregulated way creating so-called plexiform neurofibromas (PN). By blocking these enzymes, KOSELUGO slows down the growth of tumor cells and, therefore, the PN growth.

    KOSELUGO is approved in the US, EU, Japan, China and other countries for the treatment of certain pediatric patients with NF1 who have symptomatic, inoperable PN.

    KOSELUGO is approved in the US, EU, Japan and other countries for the treatment of adult patients with NF1 who have symptomatic, inoperable PN, and additional regulatory reviews are ongoing.

    KOSELUGO has been granted Orphan Drug Designation in the US, EU, Japan and other countries for the treatment of NF1.

    ULTOMIRIS® (ravulizumab-cwvz)

    ULTOMIRIS® (ravulizumab-cwvz), the longest-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. Following a loading dose, ULTOMIRIS is administered intravenously every eight weeks in adults, or every four or eight weeks in pediatric patients (based on body weight).

    ULTOMIRIS is approved in the US, EU, Japan and other countries for the treatment of certain adults with paroxysmal nocturnal hemoglobinuria (PNH) and for certain children with PNH in the US and EU.

    ULTOMIRIS is also approved in the US, EU, Japan and other countries for the treatment of certain adults and children with atypical hemolytic uremic syndrome (aHUS).

    Additionally, ULTOMIRIS is approved in the US, EU, Japan and other countries for the treatment of certain adults with generalized myasthenia gravis (gMG).

    Further, ULTOMIRIS is approved in the US, EU, Japan and other countries for the treatment of certain adults with neuromyelitis optica spectrum disorder (NMOSD).

    ULTOMIRIS is being assessed as a treatment for additional indications as part of a broad development program.

    SOLIRIS® (eculizumab)

    SOLIRIS® (eculizumab) is a first-in-class C5 complement inhibitor. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body’s immune system. When activated in an uncontrolled manner, the terminal complement cascade over-responds, leading the body to attack its own healthy cells. SOLIRIS is administered intravenously every two weeks, following an introductory dosing period.

    SOLIRIS is approved in the US, EU, Japan, China and other countries for the treatment of certain children and adults with paroxysmal nocturnal hemoglobinuria (PNH).

    SOLIRIS is also approved in the US, EU, Japan, China and other countries for the treatment of certain children and adults with atypical hemolytic uremic syndrome (aHUS).

    Additionally, SOLIRIS is approved in the US, EU, Japan, China and other countries for the treatment of certain adults with generalized myasthenia gravis (gMG), and for certain pediatric patients with gMG in the US, EU, Japan and other countries.

    Further, SOLIRIS is approved in the US, EU, Japan, China and other countries for the treatment of certain adults with neuromyelitis optica spectrum disorder (NMOSD).

    SOLIRIS is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome.

    Alexion

    Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. For more information, please visit www.alexion.us.

    AstraZeneca

    AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on Social Media @AstraZeneca.

    Media Inquiries

    US Media Mailbox: usmediateam@astrazeneca.com  

    Continue Reading

  • DFSA proposes new operational resilience regime for DIFC firms

    DFSA proposes new operational resilience regime for DIFC firms

    The proposed operational resilience framework set out in a consultation paper (8 pages / 375KB PDF) is centred around five elements: identifying critical business services; setting impact tolerances; mapping the resources and dependencies that support those services; testing resilience through severe, but plausible, scenarios; and notifying the DFSA of material disruptions immediately where a disruption to a critical business service has breached, or is reasonably close to breaching, the firm’s pre-defined impact tolerance.

    These five interlinked elements will require DFSA regulated firms to identify critical business services, set impact tolerances, map critical resources, conduct scenario testing and notify the DFSA of material disruptions. The proposed approach marks a distinctive shift away from process-driven operational risk management towards an outcome focused assessment of how disruption could cause harm to clients or the wider financial system.

    As the paper notes, the framework aligns closely with international standards, including Basel Core Principle 25 and the Basel Principles for Operational Resilience. These themselves draw on approaches adopted by the UK’s primary financial regulators – the Financial Conduct Authority (FCA) in 2021 and the Prudential Regulation Authority (PRA) in 2022 – as well as other leading regulators including the Monetary Authority of Singapore (MSA) and the Hong Kong Monetary Authority (MSA) in 2022, and the Qatar Financial Centre Regulatory Authority more recently in 2024.

    The changes will apply to all DFSA regulated firms including banks, investment firms, insurers, financial advisers and fintechs, as well as the DIFC branches of international financial service groups. The public consultation on the proposals is open until 26 May, and the proposed operational resilience framework is expected to be implemented by the end of 2026.

    All DFSA regulated firms will be required to assess whether they provide critical business services, although only firms that identify such services will be subject to the full operational resilience requirements.

    Marie Chowdhry, a financial regulation and fintech expert at Pinsent Masons, said the proposals signalled a “a shift away from traditional operational risk management toward a service focused resilience framework, with increased board accountability and regulatory scrutiny”.

    Chowdhry said the DFSA’s operational resilience proposals also marked a significant evolution in regulatory expectations for firms operating across the DIFC. “Rather than focusing solely on preventing operational failures, the proposed regime requires firms to assume that disruptions will occur and to demonstrate their ability to continue delivering critical business services within defined impact tolerances,” she said.

    Jessa White, an expert in fintech at Pinsent Masons, said many DFSA regulated firms will need to reassess how they should approach operational risk and business continuity in light of the new proposed regime. “Firms will need to identify which services are genuinely critical, set clear thresholds for tolerable disruption, map the people, processes, systems and third party dependencies that support those services, and test their resilience through severe but plausible scenarios,” she said. “Importantly, the proposals also place responsibility firmly with governing bodies to approve key outcomes, reinforcing board level accountability.”

    The DFSA expects businesses to be “be well advanced in their preparations” to comply with the new the new regime within 12 months of it coming into effect, alongside a 24-month implementation period following enactment of the rules to allow firms sufficient time to adjust to the new rules.

    Chowdhry said that although the DFSA appeared to be taking a proportionate and risk-based approach, she warned that firms should not underestimate the time and effort required to embed to adapt their businesses to comply with the new regime’s requirements. “With a proposed 24-month implementation period, firms should consider beginning preparatory work early, including gap analysis, governance planning, and engagement with group wide resilience frameworks where applicable,” she added. “The consultation paper also provides an important opportunity for firms and businesses seeking to become licensed by the DFSA to shape how the regime is finalised and applied in practice.”

    Continue Reading

  • European airports face jet fuel shortages within three weeks – Financial Times

    1. European airports face jet fuel shortages within three weeks  Financial Times
    2. Italy Sets Jet Fuel Limits at Some Airports on Supply Gap  Bloomberg.com
    3. European airport runs out of fuel as Iran war drives jet fuel prices up  Birmingham Live
    4. Northern Italian Airports Grapple With Acute Aviation Fuel Shortage as Hormuz Crisis Reaches European Skies: Everything You Need to Know  Travel And Tour World
    5. Summer could be cancelled – alarm as Europe risks running out of jet fuel  The Herald

    Continue Reading

  • Uniqlo operator posts record profit, won’t rule out price hikes

    Uniqlo operator posts record profit, won’t rule out price hikes

    Fast Retailing Co., operator of Uniqlo clothing stores, reported record sales and profits but warned that its products may become more expensive down the road due to rising oil prices.

    For the six months ending in February, Fast Retailing sales soared 14.8 percent year on year to 2.0552 trillion yen ($12.9 billion), while net profit surged 19.6 percent to 279.2 billion yen, both record highs, the company said April 9.

    For the full business year ending in August, the company forecasts revenue of 3.9 trillion yen and net profit of 480 billion yen.

    Takeshi Okazaki, a director at Fast Retailing, said the war in the Middle East will likely not have an immediate negative effect on the company’s performance.

    “The current rise in oil prices has an extremely limited direct impact on this fiscal year’s performance,” he said at the company’s interim earnings briefing on April 9.

    Iran’s effective blockade of the Strait of Hormuz has halted shipping traffic and pushed up crude oil prices. Oil-derived synthetic fibers are used in clothing, including those sold at Uniqlo stores.

    According to Fast Retailing, the company’s preparation for Uniqlo products begins a year before launch, meaning that fibers and other materials are procured at an early stage.

    “As far as what we can see through August, we have secured a clear outlook for the procurement of materials,” Okazaki said.

    However, Tadashi Yanai, chairman and CEO of Fast Retailing, did not rule out possible price increases in for the longer term.

    “In order for customers to continue buying our products, we need to endure what we can,” he said, but added, “It is not possible for only us to avoid raising prices.”

    Fiber manufacturers, such as Toray Industries Inc. and subsidiaries of Teijin Ltd. have announced price hikes for synthetic fibers used in clothing.

    Synthetic fibers are made from naphtha, a crude gasoline product refined from oil, and other petroleum-derived materials.

    Naphtha prices have also risen since the U.S.-Israeli airstrikes against Iran opened the war on Feb. 28.

    The United States and Iran agreed to a two-week cease-fire on the evening of April 7. But both sides have already accused the other of violations, and some media outlets have reported that Iran has once again sealed off the strait.

    Takahiro Kazahaya, a senior analyst at UBS Securities Japan Co. who specializes in the apparel industry, said if the closure of the strait is prolonged, “it cannot be ruled out that prices for products from next spring and summer onward will be reconsidered.”


    Continue Reading

  • Hanwha Aerospace partners with Indra for defense cooperation

    Hanwha Aerospace partners with Indra for defense cooperation

    Hanwha Aerospace has signed a memorandum of understanding (MOU) with Spanish defense company Indra Group to jointly offer armored vehicle solutions for the Chilean Army and cooperate across Latin America.

     

    The signing ceremony took place at the FIDAE 2026 International Air and Space Fair in Santiago, Chile.

     

    Dong Hyeon Kim, Head of Hanwha Aerospace’s Land Systems Business Group, Domingo Castro Fernández, Indra’s Director of Defense and Security for America, and María Dolores Carrillo Aguilera, Indra’s Business Development Director of Land Systems, and The Republic of Korea’s Ambassador to Chile, Hak-jae Kim, attended the ceremony.

     

    Under the agreement, the two companies will jointly propose a combined solution for Chile’s next-generation armored vehicle program. Hanwha Aerospace will supply its Tigon armored vehicle platforms, while Indra will provide Mission System Equipment (connectivity, situational awareness, and C2, among others) and serve as the regional coordination lead. Starting with Chile, the two companies aim to expand their cooperation across ground defense programs in the wider Latin American region.

     

    The collaboration marks a step beyond conventional equipment supply, with the two companies offering a turnkey package that integrates Hanwha Aerospace’s proven Tigon platforms with Indra’s mission system technologies.

     

    Dong Hyeon Kim, Head of Land Systems Business Group at Hanwha Aerospace, said, “Indra has defense electronics capabilities and a track record in Latin America that complement our vehicle platforms. Through this MOU, the two companies will be able to offer a more complete package to armed forces in the region.”

     

    An Indra Group spokesperson said, “This partnership creates an optimum framework for combining the core technologies and areas of excellence of both companies into a competitive, state-of-the-art product, capable of meeting high demand in the region.”

     

     

    Hanwha Aerospace

     

    Hanwha Aerospace is a global aerospace and defense company that offers a broad portfolio of products and services. These include land combat vehicles such as the world-renowned K9 Self-Propelled Howitzer and the Redback Infantry Fighting Vehicle, various other weapons systems, munitions, aircraft engine parts, and technology products and services. As South Korea’s largest aerospace and defense company, Hanwha Aerospace is engaged in the research, development, and manufacture of advanced technology systems and is spearheading the country’s space projects.

     

    For more information, visit: www.hanwhaaerospace.com

     

    Indra Group

     

    Indra Group is the foremost Spanish multinational and one of the leading European companies that focuses on defence and advanced digitalization. It stands at the forefront of the defence, space, air traffic management, mobility, and transformative technologies through Minsait, and it integrates its sovereign AI, cybersecurity, and cyberdefence capabilities into IndraMind. Indra Group is paving the way to a more secure and better-connected future through innovative solutions, trusted relationships, and the very best talent. Sustainability is an integral part of its strategy and culture in order to overcome current and future social and environmental challenges. At the close of the 2025 financial year, Indra Group posted revenues of €5.457 billion and had a local presence in 46 countries and business operations in over 140 countries.

     

    For more information, visit: https://www.indragroup.com/

    Continue Reading

  • Renault Group launches Renault Care Fleet by CareMakers: solidarity mobility at the service of local health

    Renault Group launches Renault Care Fleet by CareMakers: solidarity mobility at the service of local health

    Boulogne-Billancourt, April 10, 2026 – Through its CareMakers inclusive mobility program, Renault Group is strengthening its social commitment by launching Renault Care Fleet, a new solidarity offer dedicated to healthcare professionals working in medical deserts. This initiative aims to facilitate the travel of caregivers and to support access to care in the territories most weakened by the lack of mobility solutions.

    “Renault Care Fleet was born out of a reality on the ground: for caregivers, mobility is a work tool in its own right, yet this mobility is becoming more and more expensive. In remote and underserved areas, access to care is at stake. By offering solidarity-based mobility solutions adapted to the challenges of the regions, we are making the vehicle a daily ally for healthcare professionals and a concrete lever for access to and continuity of care,said Cléa Martinet, Renault Group Senior Vice President, Sustainable Development.

    RENAULT CARE FLEET, A SOLIDARITY OFFER FOR CAREGIVERS, TARGETED AT THE NEEDS OF THE TERRITORIES

    Renault Group is launching Renault Care Fleet, a fleet of 50 reconditioned electric Renault ZOE E-Tech electric, available from 10 April in the Grand Est, Centre-Val de Loire and Alpes-Maritimes regions. Aimed at nurses, nursing assistants and midwives working at home, this offer aims to make mobility a lever for action in the service of care.

    The offer is based on a solidarity lease from €99 per month (48 months, with a first rent increased by
    €1,300 including tax[1]), including a charge pass. It guarantees a cost of use divided by four compared to a combustion vehicle, a range of up to 395 km (WLTP) with fast charging and use without local emissions.

    The procedure is carried out on the www.caremakersmobility.com/fr/carefleet website, allows you to check eligibility for the scheme and, if necessary, to be contacted by the point of sale.

    FACILITATING ACCESS TO CARE THROUGH ACCESSIBLE AND RESPONSIBLE MOBILITY

    In France, home health professionals travel tens or even hundreds of kilometres every day to ensure an essential presence with patients, particularly in rural and peri-urban areas. In these territories with low medical density, mobility directly conditions the ability to maintain a long-term healthcare presence.

    However, the increase in the costs of travel, fuel, maintenance and wear and tear weakens the economic balance of these professions and complicates the organisation of rounds.

    This logistical pressure has direct consequences: increased fatigue, reduced time with patients and difficulty covering certain areas.

    “I see between 27 and 30 patients a day. Between inflation and the rise in petrol and diesel prices, there are many nursing practices that are closing.”

    Aurore, independent nurse

    “When we go to see customers very far away, we are not very profitable because we spend time on the road.”

    Emmanuelle, midwife

    This new offer is therefore fully in line with the Group’s strategy to combine social inclusion, local roots and the transition to more sustainable mobility. To raise awareness of the CareMakers program among a wider audience, Renault Group partnered with Publicis to develop a campaign explaining the Renault Care Fleet offer:

    Link to the video: https://youtu.be/JteM7aOuUHc

    CareMakers: an inclusive mobility program with a proven track record

    CareMakers is Renault Group’s solidarity mobility programme, launched in 2012, to enable people who are not eligible for a traditional car loan to access an affordable mobility solution. By relying on a network of local integration actors and financial partners (ADIE and the Micro-Credit Institute), CareMakers supports financially constrained groups to facilitate access to or maintenance in employment.

    By combining microcredit, solidarity rental, new or reconditioned vehicles at reduced prices and maintenance at cost rate, CareMakers aims to remove a major obstacle to employment: the lack of mobility. This scheme, which is part of Renault’s sustainable development strategy focused on inclusion, has already enabled 4,000 beneficiaries to find or keep a job, making mobility a real lever for equal opportunities.


    [1] Possibility of financing by micro-credit depending on income conditions and within the framework of the CareMakers program

    Continue Reading

  • Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement for Issuance of New Shares or Disposal of Treasury Shares

    Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement for Issuance of New Shares or Disposal of Treasury Shares

    TOKYO, Japan ― Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today announced that Renesas has withdrawn the Shelf Registration Statement filed on July 18, 2025, and has filed a new Shelf Registration Statement for the issuance of new shares or the disposal of treasury shares. 

    On July 18, 2025, Renesas decided to grant the restricted stock units (“RSUs”) to employees of Renesas and its subsidiaries on August 1, 2025 under the stock compensation plan (the “Plan”) and filed the aforementioned Shelf Registration Statement for the issuance of new shares or the disposal of treasury shares. 

    Today, Renesas has decided to grant new RSUs, restricted stock units (restricted stock type) (“RSUs (RS Type)”), performance share units (“PSUs”), and performance share units (restricted stock type) (“PSUs (RS Type)”) to directors, executive officers, executive corporate officers and employees of Renesas, and to employees of its subsidiaries effective May 1, 2026. 

    (1)  Purpose of Shelf Registration See above.
    (2)  Class of Securities to be Offered Shares of common stock of Renesas
    (3)  Scheduled Issue Period For the period from the scheduled effective date of the Shelf Registration to the date that is two years after such scheduled effective date (From April 18, 2026 to April 17, 2028)
    (4)  Scheduled Issue Amount Up to 9,300 million yen
    (5)  Use of Proceeds Shares of common stock of Renesas will be allotted to the relevant directors, executive  officers,  executive corporate officers and employees in exchange for the contribution of the monetary compensation receivables provided to each relevant directors, executive  officers, executive corporate officers and employees, and no proceeds will be gained by Renesas

    (Details of the Plan) 

    (1)  Eligible Grantees

    Directors, executive officers, executive corporate officers and employees of Renesas and its subsidiaries.

    (2)  Overview of RSU

    The RSUs granted under the Plan are stock compensation in which Renesas grants the number of units predetermined by Renesas to the Eligible Grantees in advance, and then delivers shares of its common stock to the Eligible Grantees in accordance with the number of units that vest based on the service continuation period. In principle, in the case of Eligible Grantees other than outside directors, one-third of the number of units granted (corresponding to three years) will vest upon the completion of each one-year period, and, in the case of outside directors, the total number of units granted (corresponding to one year) will vest upon the completion of one year of continuous service.

    With respect to the RSUs that may be granted in connection with any special situation, such as when RSUs are granted to executives and employees of an acquired company where stock compensation granted by the acquired company are extinguished, or when RSUs are granted in connection with a reduction in the basic salary, Renesas may vest the units in a period different from above.

    (3)  Overview of RSU (RS Type)

    The RSUs (RS Type) granted under the Plan are stock compensation in which Renesas 

    grants the number of units predetermined by Renesas to the Eligible Grantees in advance, and then delivers shares of its common stock to the Eligible Grantees in accordance with the number of units that vest based on the service continuation period, subject to transfer restrictions that are lifted upon the Eligible Grantee’s termination of service or employment from Renesas or its subsidiaries. In principle, in the case of Eligible Grantees other than outside directors, one-third of the number of units granted (corresponding to three years) will vest upon completion of each one-year period, and, in the case of outside directors, the total number of units granted (corresponding to one year) will vest upon the completion of one year of continuous service.

    With respect to the RSUs (RS Type) that may be granted in connection with any special situation, such as when RSUs (RS Type) are granted to executives and employees of an acquired company where stock compensation granted by the acquired company are extinguished, or when RSUs (RS Type) are granted in connection with a reduction in the basic salary, Renesas may vest the units in a period different from above.

    (4)  Overview of PSU

    The PSUs granted under the Plan are stock compensation in which Renesas provides the Eligible Grantees in advance with the units in a number determined by it; vests the units in a number determined in accordance with the growth rate of the total shareholder return of Renesas during a three-year period from April 1 of the year in which the units are granted; and then delivers shares of Renesas’ common stock to such Eligible Grantees in accordance with the vested units.

    On the basis of the number of units granted, the number of PSUs will be determined by multiplying a certain coefficient determined in accordance with the growth rate of total shareholders return of Renesas for the period of three years from April 1 of the year in which the PSUs are provided.

    (5)  Overview of PSU (RS Type)

    The PSUs (RS Type) granted under the Plan are stock compensation in which Renesas provides the Eligible Grantees in advance with the units in a number determined by it; vests the units in a number determined in accordance with the growth rate of the total shareholder return of Renesas during a three-year period from April 1 of the year in which the units are granted; and then delivers shares of Renesas’ common stock to such Eligible Grantees in accordance with the vested units, subject to transfer restrictions that are lifted upon the Eligible Grantee’s termination of service or employment from Renesas and its subsidiaries.

    On the basis of the number of units granted, the number of PSUs (RS Type) will be determined by multiplying a certain coefficient determined in accordance with the growth rate of total shareholders return of Renesas for the period of three years from April 1 of the year in which the PSUs (RS Type) are provided.

    (6)  Method and Timing of Delivery of Shares of Renesas

    On each vesting date, Renesas, pursuant to determination of the Representative Executive Officer, will allot to the Eligible Grantees the shares of Renesas’ common stock corresponding to the number of units that vest: for RSUs and PSUs, shares of Renesas’ common stock (one share per unit); and for RSUs (RS-type) and PSUs (RS-type), shares of Renesas’ common stock (one share per unit) that are subject to transfer restrictions that are lifted upon the participant’s resignation or retirement from Renesas and its subsidiaries, in exchange for the contribution in kind by such Eligible Grantees of all of the monetary compensation receivables provided to such Eligible Grantees, by way of issuance of new shares of Renesas’ common stock, disposal of treasury shares, or other methods of delivery.

    The payment amount per share delivered upon vesting of the units under the Plan is the closing price of the shares of Renesas’ common stock on the Tokyo Stock Exchange on the business day immediately prior to the date of the resolution of the determination of the Representative Executive Officer for the delivery of Renesas’ common stock (or, if no transaction is effected on the same day, the closing price on the most recent trading day prior thereto).

    (7)  Handling at the time of retirement

    The vesting of the units shall be made, in principle, subject to the condition that the Eligible Grantees are directors, executive officers, executive corporate officers, or employees, etc., of Renesas or its subsidiaries at the time of the vesting. However, even if the Eligible Grantees lose their position prior to the vesting of the units, in the event of losses of positions due to causes for the employment contract, etc. or other special circumstances, the number of the shares of Renesas’ common stock to be delivered and the timing of the delivery may be adjusted by the method provided by Renesas. The shares of Renesas’ common stock to be delivered under RSUs (RS Type) and PSUs (RS Type) upon the termination of an Eligible Grantee’s position as a director, executive officer, executive corporate officer, employee or any other similar position of Renesas and its subsidiaries shall be the shares of Renesas’ common stock that are not subject to transfer restrictions.

    (8) Transfer restrictions of Renesas’ common stock delivered under RSUs (RS Type) and PSUs (RS Type)

    The Eligible Grantee may not transfer, pledge, or otherwise dispose of the shares of Renesas’ common stock delivered upon vesting of RSUs (RS Type) or PSUs (RS Type) from the date of receipt until the date on which the Eligible Grantee ceases to hold any position as a director, executive officer, executive corporate officer or employee of Renesas or its subsidiaries. In addition, during the period until the expiration of the transfer restriction period, if the Eligible Grantee breaches any provision of the terms and conditions of the Plan established by Renesas, or violates any laws, regulations or internal rules and is dismissed or subject to disciplinary action equivalent to dismissal or any similar action, Renesas will acquire such shares without compensation.

    About Renesas Electronics Corporation

    Renesas Electronics Corporation (TSE:6723) empowers a safer, smarter and more sustainable future where technology helps make our lives easier. A leading global provider of microcontrollers, Renesas combines our expertise in embedded processing, analog, power and connectivity to deliver complete semiconductor solutions. These Winning Combinations accelerate time to market for automotive, industrial, infrastructure and IoT applications, enabling billions of connected, intelligent devices that enhance the way people work and live. Learn more at renesas.com. Follow us on LinkedInFacebookTwitterYouTube, and Instagram.

    (FORWARD-LOOKING STATEMENTS)

    The statements in this press release with respect to the plans, strategies and financial outlook of Renesas and its consolidated subsidiaries (collectively “we”) are forward-looking statements involving risks and uncertainties. Such forward-looking statements do not represent any guarantee by management of future performance. In many cases, but not all, we use such words as “aim,” “anticipate,” “believe,” “continue,” “endeavor,” “estimate,” “expect,” “initiative,” “intend,” “may,” “plan,” “potential,” “probability,” “project,” “risk,” “seek,” “should,” “strive,” “target,” “will” and similar expressions to identify forward-looking statements. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements discuss future expectations, identify strategies, contain projections of our results of operations or financial condition, or state other forward-looking information based on our current expectations, assumptions, estimates and projections about our business and industry, our future business strategies and the environment in which we will operate in the future. Known and unknown risks, uncertainties and other factors could cause our actual results, performance or achievements to differ materially from those contained or implied in any forward-looking statement, including, but not limited to, general economic conditions in our markets, which are primarily Japan, North America, Asia, and Europe; demand for, and competitive pricing pressure on, products and services in the marketplace; ability to continue to win acceptance of products and services in these highly competitive markets; and fluctuations in currency exchange rates, particularly between the yen and the U.S. dollar. Among other factors, downturn of the world economy; deteriorating financial conditions in world markets, or deterioration in domestic and overseas stock markets, may cause actual results to differ from the projected results forecast.

    This press release is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither we nor our advisors or representatives are under an obligation to update, revise or affirm.

    ###


    Continue Reading

  • Stock market today: Live updates

    Stock market today: Live updates

    Traders work on the floor of the New York Stock Exchange during morning trading on April 08, 2026 in New York City.

    Michael M. Santiago | Getty Images

    Stock futures were little changed early Friday as traders kept an eye on the fragile two-week ceasefire between the U.S. and Iran.

    S&P 500 futures were little changed, while Nasdaq 100 futures traded about 0.15% higher. Futures tied to the Dow Jones Industrial Average were trading flat.

    Stocks advanced on Thursday, extending their gains this week after President Donald Trump agreed to pause attacks on Iran for two weeks. The S&P 500 rose 0.62%, while the Nasdaq Composite advanced 0.83%. The 30-stock Dow climbed 275.88 points, or 0.58%, in the session and crept into positive territory for 2026.

    Oil prices came off their highs of the day and the S&P 500 rose after Israeli Prime Minister Benjamin Netanyahu said that the country had agreed to negotiate with Lebanon “as soon as possible.” Tehran’s parliamentary speaker Mohammad Bagher Ghalibaf cited Israel’s continued attacks on Lebanon as a violation of the ceasefire agreement between the U.S. and Iran.

    On Tuesday night, Trump agreed to a two-week extension of his deadline for Iran to reopen the Strait of Hormuz. The Middle East conflict, which has already been going on for five weeks, resulted in the closure of the key waterway.

    Stocks surged on Wednesday following the news of the ceasefire, with all three major indexes jumping more than 2%. The Dow notched its best day since April 2025.

    Stephen Parker, co-head of global investment strategy at J.P. Morgan Private Bank, believes that the relief rally has sustainable legs going forward.

    “The size of the drawdown that we’ve seen in equity markets, particularly in the U.S., probably doesn’t feel big enough relative to the move and the shock that we saw in energy markets, but I think that’s reflective of a view that energy prices are likely to come down,” he said on CNBC’s “Closing Bell: Overtime” on Thursday afternoon.

    “Our base case is one where energy prices continue to gradually move lower over the next three to six months,” he added. “We take a little bit of a hit to growth, a little bit of a pickup in inflation, but overall, that’s still a very constructive environment for equities, particularly as we get into earnings season, which we think will be really positive.”

    The major averages are on pace for solid weekly gains. The S&P 500 has jumped nearly 3.7% through Thursday’s close, tracking for its best week since November. The Dow has gained 3.6% week to date, while the Nasdaq is on pace to rise 4.3%.

    On the economic front, traders will watch for March’s consumer price index reading. Economists polled by Dow Jones see a month over month increase of 0.9% and a 3.3% gain over the prior 12 months. Durable goods and factory orders are also due out.

    Continue Reading

  • Top 10 op risks: AI upends risk taxonomies – Risk.net

    1. Top 10 op risks: AI upends risk taxonomies  Risk.net
    2. AI governance will decide cloud strategy in India — not just cost or performance  cio.com
    3. ‘Learning has to be ongoing’: LRN’s Patsy Doerr on why culture and governance define AI success  | Governance Intelligence
    4. Moving From AI Risk To AI Governance  Forbes
    5. Internal audit’s role in guiding AI responsibly  Accounting Today

    Continue Reading